Published in Drug Metab Dispos on January 31, 2013
A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives. Drug Metab Dispos (2014) 0.79
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. Int J Cancer Res Mol Mech (2015) 0.77
Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus (2013) 0.77
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. Br J Clin Pharmacol (2016) 0.76
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Drug metabolism and variability among patients in drug response. N Engl J Med (2005) 4.65
Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat (2002) 3.19
Sources of estrogen and their importance. J Steroid Biochem Mol Biol (2003) 2.54
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98
The enzymes of detoxication. J Biol Chem (1990) 1.94
Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis (1991) 1.74
Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol (1997) 1.61
Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res (2000) 1.55
Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med (2003) 1.51
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos (2005) 1.41
Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology (2001) 1.38
Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology (2004) 1.30
Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res (2004) 1.30
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev (2007) 1.26
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos (2001) 1.21
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol (2010) 1.18
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract (2007) 1.17
Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics (2000) 1.17
Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem (2000) 1.16
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol (1998) 1.15
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet (2005) 1.14
Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol (2001) 1.13
Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut (2002) 1.12
Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis (2008) 1.11
Uterine sarcoma associated with tamoxifen use. N Engl J Med (2002) 1.11
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res (2003) 1.08
Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet (2005) 1.01
Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos (2009) 0.98
Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet (2005) 0.97
Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol (2008) 0.95
Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol (2005) 0.93
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs (2008) 0.92
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J (2007) 0.91
A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics (2009) 0.91
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev (2010) 0.88
Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat (2009) 0.88
The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res (2011) 0.88
Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics. Drug Metab Dispos (2012) 0.87
Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics (2011) 0.86
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet Genomics (2011) 0.84
Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol (2005) 0.84
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer. Expert Rev Anticancer Ther (2008) 0.83
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer (2006) 0.82
Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms. Pharmacogenet Genomics (2012) 0.76
OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes (2006) 2.77
Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. Chem Res Toxicol (2007) 2.53
Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J Clin Endocrinol Metab (2008) 2.07
Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab (2010) 1.94
Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab (2009) 1.75
Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev (2012) 1.73
Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes (2007) 1.67
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab (2005) 1.52
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J Lipid Res (2006) 1.50
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab (2006) 1.42
Global gene expression profiles of subcutaneous adipose and muscle from glucose-tolerant, insulin-sensitive, and insulin-resistant individuals matched for BMI. Diabetes (2011) 1.31
Pioglitazone induces apoptosis of macrophages in human adipose tissue. J Lipid Res (2006) 1.19
Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans. Arterioscler Thromb Vasc Biol (2009) 1.17
Phenotypic anchoring of acetaminophen-induced oxidative stress with gene expression profiles in rat liver. Toxicol Sci (2006) 1.16
Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol (2009) 1.11
Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res (2011) 1.11
Insulin resistance in African-American and Caucasian women: differences in lipotoxicity, adipokines, and gene expression in adipose tissue and muscle. J Clin Endocrinol Metab (2010) 1.10
Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev (2004) 1.09
Formaldehyde-induced histone modifications in vitro. Chem Res Toxicol (2008) 1.09
Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics Clin Appl (2007) 1.08
Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology (2009) 1.08
Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab (2010) 1.05
Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer (2012) 1.02
Effects of benzyl isothiocyanate and phenethyl isothiocyanate on DNA adduct formation by a mixture of benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis (2002) 1.02
Physical activity, diet, and pancreatic cancer: a population-based, case-control study in Minnesota. Nutr Cancer (2009) 1.00
Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci (2010) 1.00
Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.00
Genetic variation in bone morphogenetic protein and colon and rectal cancer. Int J Cancer (2011) 0.99
A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate. Rapid Commun Mass Spectrom (2008) 0.98
Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer. PLoS One (2011) 0.97
1,3-Butadiene: Biomarkers and application to risk assessment. Chem Biol Interact (2010) 0.97
NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J Mol Biol (2004) 0.96
Common genetic polymorphisms in the 5'-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity. Pharmacogenet Genomics (2005) 0.95
Exposure-response of 1,2:3,4-diepoxybutane-specific N-terminal valine adducts in mice and rats after inhalation exposure to 1,3-butadiene. Toxicol Sci (2010) 0.95
Molecular epidemiological studies in 1,3-butadiene exposed Czech workers: female-male comparisons. Chem Biol Interact (2006) 0.94
Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice. Exp Gerontol (2008) 0.93
Low utilization of circulating glucose after food withdrawal in Snell dwarf mice. J Biol Chem (2007) 0.92
High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. Am J Clin Oncol (2016) 0.92
Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry (2007) 0.91
Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer Causes Control (2011) 0.89
Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer (2012) 0.88
Iminohydantoin lesion induced in DNA by peracids and other epoxidizing oxidants. J Am Chem Soc (2009) 0.88
Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. Pharmgenomics Pers Med (2011) 0.88
Cooperative effects for CYP2E1 differ between styrene and its metabolites. Xenobiotica (2013) 0.88
Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics. Drug Metab Dispos (2012) 0.87
Future directions in butadiene risk assessment and the role of cross-species internal dosimetry. Chem Biol Interact (2007) 0.87
Accurate quantitation of standard peptides used for quantitative proteomics. Proteomics (2009) 0.87
Measurement of 3-hydroxyisovaleric acid in urine from marginally biotin-deficient humans by UPLC-MS/MS. Anal Bioanal Chem (2011) 0.87
Comparison of three oxidative stress biomarkers in a sample of healthy adults. Biomarkers (2009) 0.86
Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control (2010) 0.86
Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts. Chem Res Toxicol (2009) 0.86
Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans. J Nutr (2011) 0.86
Sequence variants in antioxidant defense and DNA repair genes, dietary antioxidants, and pancreatic cancer risk. Int J Mol Epidemiol Genet (2011) 0.85
Profiling of ecdysteroids in complex biological samples using liquid chromatography/ion trap mass spectrometry. Rapid Commun Mass Spectrom (2006) 0.84
CYP2E1 metabolism of styrene involves allostery. Drug Metab Dispos (2012) 0.84
Feasibility and reproducibility of left ventricular rotation by speckle tracking echocardiography in elderly individuals and the impact of different software. PLoS One (2013) 0.83
Sulfotransferase genetic variation: from cancer risk to treatment response. Drug Metab Rev (2013) 0.82
A 2-iminohydantoin from the oxidation of guanine. Chem Res Toxicol (2006) 0.82
A transcranial magnetic stimulation study of the effects of cannabis use on motor cortical inhibition and excitability. Neuropsychopharmacology (2009) 0.82
Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer. Mol Carcinog (2011) 0.81
Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue. Pharmgenomics Pers Med (2013) 0.81
Quantitative analysis of N-terminal valine peptide adducts specific for 1,2-epoxy-3-butene. Chem Biol Interact (2006) 0.81
Effect of feeding grape pomace on selected metabolic parameters associated with high fructose feeding in growing Sprague-Dawley rats. J Med Food (2011) 0.80
Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett (2012) 0.80
Age-, gender-, and species-dependent mutagenicity in T cells of mice and rats exposed by inhalation to 1,3-butadiene. Chem Biol Interact (2006) 0.80
LC/MS/MS method for the quantitation of trans-2-hexenal-derived exocyclic 1,N(2)-propanodeoxyguanosine in DNA. Chem Res Toxicol (2006) 0.80
Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects. Pharmgenomics Pers Med (2013) 0.80
Flanking bases influence the nature of DNA distortion by platinum 1,2-intrastrand (GG) cross-links. PLoS One (2011) 0.79
Differences in butadiene adduct formation between rats and mice not due to selective inhibition of CYP2E1 by butadiene metabolites. Toxicol Lett (2013) 0.79
Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett (2010) 0.79
Measurement of acylcarnitine substrate to product ratios specific to biotin-dependent carboxylases offers a combination of indicators of biotin status in humans. J Nutr (2012) 0.78
Genetic variability in energy balance and pancreatic cancer risk in a population-based case-control study in Minnesota. Pancreas (2014) 0.78
Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus (2013) 0.77
Marginal biotin deficiency can be induced experimentally in humans using a cost-effective outpatient design. J Nutr (2011) 0.77
Association between GSTM1 copy number, promoter variants and susceptibility to urinary bladder cancer. Int J Mol Epidemiol Genet (2012) 0.77
GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer. Pharmgenomics Pers Med (2013) 0.77
Differential promoter activities of functional haplotypes in the 5'-flanking region of human sulfotransferase 1A1. J Biochem Mol Toxicol (2012) 0.77
Identification and characterization of 2'-deoxyadenosine adducts formed by isoprene monoepoxides in vitro. Chem Res Toxicol (2011) 0.76
Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells. BMC Clin Pathol (2014) 0.76
Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines. Cancer Biol Ther (2015) 0.76
Pharmacogenetics of SULT1A1. Pharmacogenomics (2014) 0.75
Regulation of small ubiquitin-like modifier-1, nuclear receptor coreceptor, histone deacetylase 3, and peroxisome proliferator-activated receptor-γ in human adipose tissue. Metab Syndr Relat Disord (2012) 0.75